Tag Archives: Alzheimer’s neuropathology

Clinton Campaign Announces Investment Plan for Alzheimer’s Disease

LuMind Research Down Syndrome Foundation applauds the development and announcement by the Clinton presidential campaign of a formal plan for new investment to prevent, treat, and make an Alzheimer’s disease cure possible by 2025, which includes a commitment to reach the $2 billion annual funding level for NIH’s dementia research. You can read more details on Clinton’s announced plan in the following article.

We join with many of our other colleagues and partners in the Down syndrome and Alzheimer’s disease communities in encouraging all of the presidential campaigns to develop and support formal proposals for advancing Alzheimer’s disease and dementia research.

This research is especially important for individuals with Down syndrome since virtually all develop the brain characteristics of Alzheimer’s disease earlier, by their 40’s, and the majority subsequently progress to earlier onset of the associated dementia. In November, NIH announced significant new grant awards to find Alzheimer’s biomarkers in Down syndrome.

LuMind RDS is the leading source of private funding for Down syndrome cognition research, including funding initiatives to identify and develop effective new therapies to prevent and halt the progression of the earlier onset Alzheimer’s disease in people with Down syndrome and help avoid the loss of gains they achieve throughout their lives. If you would like to support this research, please consider a donation during our Annual Appeal.

UCSD Study Unraveling the Complexities between Down Syndrome and Alzheimer’s Disease

UCSD Study Ds ADOur friends at University of California, San Diego are helping to unravel the complexities of Down syndrome and Alzheimer’s disease. A news report from WFMZ in San Diego refers to a three-year pilot project involving a relatively small set of individuals with Down syndrome, like the impressive Jonathan Shirley.

Dr. Mike Rafii, the principal investigator on this pilot Down Syndrome Biomarker Initiative (DSBI) and his research colleagues at UCSD, are investigating the similarities between the brains of aging people with Down syndrome and those with Alzheimer’s disease, both developing buildup of characteristic amyloid plaques. Individuals with Down syndrome develop these amyloid plaques earlier by the age of 40.

LuMind Foundation’s Chief Scientific Officer, Dr. Michael Harpold, is a member of the DSBI steering committee and is collaborating with Dr. Rafii and others on developing a larger private-public partnership DSBI study. That program is currently in the planning and development stage. To see the news segment in full and watch a video of Jonathan Shirley, please click here.

The Connection between Ds and Alzheimer’s Disease

All adults with Down syndrome over 35-40 years of age develop the characteristic Alzheimer’s neuropathology, including the formation of beta-amyloid plaques, with earlier onset of dementia developing in more than 70% of individuals. Read more from a Science Daily article  and review the connections to the greater Alzheimer’s community.